Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Poll|Articles|November 5, 2025
Poll: Has the Shortage of IV Ativan Impacted Your Practice?
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- The shortage of IV Ativan poses challenges in managing psychiatric conditions, particularly catatonia, necessitating alternative treatment strategies.
- Increased incidences of catatonia may occur due to the difficulty in accessing IV Ativan, impacting patient care.
Answer our poll!
Advertisement
Psychiatric Times contributors have noted a challenge in their psychiatric practice: the shortage of intravenous (IV) Ativan.
Has the shortage of IV Ativan impacted your practice?
Have you noticed an increase in catatonia amongst your patients?
If you have noticed an increase in catatonia or a difficulty in accessing IV Ativan, reach out to us at
Advertisement
Related to this article
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
AI might streamline psychiatric intake with avatar interviews and EHR-linked decision support, adding guardrails against hallucinations and enabling measurement-driven precision predictions.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5